KR20250053870A - 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 - Google Patents

톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR20250053870A
KR20250053870A KR1020257007164A KR20257007164A KR20250053870A KR 20250053870 A KR20250053870 A KR 20250053870A KR 1020257007164 A KR1020257007164 A KR 1020257007164A KR 20257007164 A KR20257007164 A KR 20257007164A KR 20250053870 A KR20250053870 A KR 20250053870A
Authority
KR
South Korea
Prior art keywords
cell lymphoma
decitabine
tolinapant
lymphoma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257007164A
Other languages
English (en)
Korean (ko)
Inventor
마틴 존 심스
조지 앨버트 워드
해롤드 키어
아람 오가네시안
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20250053870A publication Critical patent/KR20250053870A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020257007164A 2022-08-31 2022-11-04 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 Pending KR20250053870A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
US63/374,137 2022-08-31
PCT/IB2022/060652 WO2024047394A1 (en) 2022-08-31 2022-11-04 Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Publications (1)

Publication Number Publication Date
KR20250053870A true KR20250053870A (ko) 2025-04-22

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257007164A Pending KR20250053870A (ko) 2022-08-31 2022-11-04 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법

Country Status (9)

Country Link
US (1) US20240082286A1 (https=)
EP (1) EP4580635A1 (https=)
JP (1) JP2025529240A (https=)
KR (1) KR20250053870A (https=)
AU (1) AU2022476674A1 (https=)
CA (1) CA3266274A1 (https=)
MX (1) MX2025002312A (https=)
TW (1) TW202410893A (https=)
WO (1) WO2024047394A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
US12239653B2 (en) * 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Also Published As

Publication number Publication date
TW202410893A (zh) 2024-03-16
US20240082286A1 (en) 2024-03-14
WO2024047394A1 (en) 2024-03-07
CA3266274A1 (en) 2024-03-07
JP2025529240A (ja) 2025-09-04
AU2022476674A1 (en) 2025-04-17
MX2025002312A (es) 2025-04-02
EP4580635A1 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
US12258346B2 (en) Substituted 6-azabenzimidazole compounds
US20230364086A1 (en) Combination therapies with ehmt2 inhibitors
US12208141B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
BR102019002873A2 (pt) inibidores de pd-1/pd-l1
TW202014193A (zh) 包含碳環核苷酸之2’3’－環二核苷酸
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
CA3234909A1 (en) Pyridizin-3(2h)-one derivatives
JP2024542248A (ja) Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
RS64936B1 (sr) Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona
KR20250053870A (ko) 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법
CN116113406B (zh) Gas41抑制剂及其使用方法
US20250186451A1 (en) Methods of treating cancer with iap antagonist compounds and combination therapies
CN118488946A (zh) Ikaros锌指家族降解剂及其用途
CN118488948A (zh) Ikaros锌指家族降解剂及其用途
TW202005654A (zh) ２，２，─環二核苷酸
CN120112288A (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途
HK40121467A (zh) Kras g12d调节化合物
US20260070915A1 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidin-2-amines as selective cdk2/4 inhibitors
HK40058418B (zh) 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
HK40114167A (zh) Ikaros锌指家族降解剂及其用途
CN118591537A (zh) Parp7抑制剂
HK40114166A (zh) Ikaros锌指家族降解剂及其用途
HK40112835A (zh) 二酰基甘油激酶调节化合物
HK40092944B (zh) 桥连三环氨基甲酰基吡啶酮化合物及其用途
HK40092944A (zh) 桥连三环氨基甲酰基吡啶酮化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250304

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application